Opinion: Some bipartisan support for biosimilars is good. More would be better
For lawmakers committed to delivering real results for patients and taxpayers, policies that would stimulate the biosimilars market are an obvious solution.
In today’s hyperpartisan and gridlocked political climate, we should seize any opportunity for bipartisan agreement that benefits the American public — especially one that can lower health care costs, like greater use of biosimilars.
During the eight-hour markup of Speaker Nancy Pelosi’s drug pricing bill (), more than 300 amendments were submitted. Only one passed: from Reps. Kurt Schrader (D-Ore.) and Greg Gianforte (R-Mont.), which they had previously introduced as a bipartisan bill called the BIOSIM Act. This amendment would provide
